Endothelial Cell News 2.00 January 9, 2017 | |
| |
TOP STORYThe Role of Fatty Acid β-Oxidation in Lymphangiogenesis Scientists report that in transgenic mouse models, lymphatic endothelial cell specific loss of CPT1A, a rate-controlling enzyme in fatty acid β-oxidation, impairs lymphatic development. [Nature] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Lymphatic Endothelial Cells Produce M-CSF Causing Massive Bone Loss in Mice The authors investigated if lymphatic endothelial cells (LECs) affect osteoclasts to cause a Gorham-Stout disease osteolytic phenotype in mice. They examined the effect of a mouse LEC line on osteoclastogenesis in co-cultures. [J Bone Miner Res] Abstract Researchers deployed an in vitro co-culture system based on direct contact of cancer cells with endothelial cells, mimicking the tumor microenvironment. Metabolism of colon and ovarian cancer cell lines was profiled with non-targeted metabolic approaches at different time points in the first 48 hours after co-culture was established. [Sci Rep] Full Article Scientists studied the effects of TNFα and cigarette smoke extract on human coronary artery endothelial cells under oscillatory, normal laminar and elevated laminar shear stress for a period of 72 hours. [Sci Rep] Full Article Scientists investigated the effects of laminar shear stress on the guanosine triphosphate cyclohydrolase (GTP)/tetrahydrobiopterin pathway and endothelial repair capacity of circulating endothelial progenitor cells in hypertension. [J Hypertens] Abstract Investigators explored the effects and possible mechanisms of NLRP3 inflammasome in endothelial cells senescence. Results showed an increment of pro-inflammatory cytokine interleukin−1β secretion and caspase-1 activation during the senescence of endothelial cells induced by bleomycin. [Int J Biochem Cell Biol] Abstract Researchers reported on the effect of atrial natriuretic peptide on the anti-fibrotic and anti-inflammatory effects on bleomycin-induced pulmonary fibrosis in mice. [Respir Res] Full Article Recently, researchers found that transforming growth factor-β1 (TGF-β1) first upregulates and then downregulates the expression of syndecan-4, a transmembrane heparan sulfate proteoglycan, via the TGF-β receptor ALK5 in the cells. To identify the intracellular signal transduction pathway that mediates this modulation, bovine aortic endothelial cells were cultured and treated with TGF-β1. [J Cell Biochem] Abstract The authors employed in vitro studies with a cyclooxygenase-2 expressing and VEGF-C/D-producing murine breast cancer cell line C3L5 and a rat mesenteric lymphatic endothelial cell (LEC) line and in vivo studies in nude mice to determine whether tumor or host-derived PGE2 has any direct effect on lymphangiogenesis, and if so, whether EP4 receptors on LECs play any role. [BMC Cancer] Full Article | |
| |
REVIEWSReverse Transendothelial Cell Migration in Inflammation: To Help or to Hinder? Investigators review the evidence that supports both reverse transendothelial migration and reverse interstitial migration within tissues, with particular emphasis on some of the more recent studies that finally hint at potential mechanisms. [Cell Mol Life Sci] Abstract Of Hemangioblast, Hemogenic Endothelium and Primitive versus Definitive Hematopoiesis The types of progenitors generated during the successive stages of embryonic blood development are now fairly well characterized. The terminology used to describe these waves, however, can still be confusing. What is truly primitive? What is uniquely definitive? Are all blood cells, including the primitive wave, derived from hemogenic endothelium? Is the hemangioblast an in vitro artefact or is this mesoderm entity also present in the developing embryo? The authors discuss the latest findings and propose some consensus relating to these controversial issues. [Exp Hematol] Abstract Visit our reviews page to see a complete list of reviews in the endothelial cell research field. | |
| |
INDUSTRY NEWSFDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization Genentech announced that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) 0.5 mg for the treatment of patients with myopic choroidal neovascularization (mCNV), a complication of severe near-sightedness that can lead to blindness. Lucentis is the first FDA-approved anti-vascular endothelial growth factor therapy to treat mCNV in the U.S. [Genentech, Inc.] Press Release GenVec, Inc. announced that it has entered into an exclusive option agreement with Washington University in St. Louis to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting. If the option is exercised, the license will allow broad utilization of technology developed by David T. Curiel, M.D., Ph.D., professor of radiation oncology and Jeffrey Arbeit, M.D., professor of surgery at Washington University School of Medicine. [GenVec, Inc.] Press Release TOT Biopharm Co., Ltd. and Lee’s Pharmaceutical Holdings Limited jointly announced that Lee’s Pharm, through its wholly-owned subsidiary Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited has acquired the exclusive license of TAB014, the monoclonal antibody drug developed and manufactured by TOT Biopharm, within China. TAB014 is a new antibody product that can be used to treat wet age-related macular degeneration and other eye diseases. [TOT Biopharm Company Limited (PR Newswire Association LLC.)] Press Release | |
| |
POLICY NEWSFASEB Launches Survey on Shared Research Resources FASEB launched a survey of researchers’ experiences with shared research resources. [Federation of American Societies for Experimental Biology] Editorial US Scientists Fear New Restrictions on Fetal-Tissue Research House Republicans conclude that tissue from aborted fetuses is of limited value for research and seek to reduce funding. [Nature News] Editorial
| |
EVENTSNEW Mouse Development, Stem Cells & Cancer Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Tumor Angiogenesis (Thomas Jefferson University) NEW Research Scientist – Molecular Cell Biology (Medical Research Council) NEW Postdoctoral Associate – Molecular Biology (Virginia Commonwealth University) Postdoctoral Scientist – Molecular Cell Biology (Medical Research Council) Assistant Professor – Regenerative Medicine (University of Cincinnati) Postdoctoral Position – Endothelial Interactions in Vascular Disease (University of Pittsburgh) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Endothelial Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Endothelial Cell News Volume 2.00 | Jan 9 2017